AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-40. **(Canceled)**

41. **(New)** A method of enhancing presentation of an antigen to an immune cell in a subject, comprising administering to the subject a complex comprising said antigen linked to a binding agent which binds to FcγRI on an antigen-presenting cell without being blocked by the natural ligand for the receptor, wherein said complex is administered in a pharmacologically acceptable medium.

42. **(New)** The method of claim 41, wherein the binding agent comprises an antibody, or an antigen binding fragment thereof.

43. **(New)** The method of claim 41, wherein the antigen is covalently crosslinked to the binding agent.

44. **(New)** The method of claim 41, wherein the binding agent comprises a bispecific antibody or a heteroantibody having a binding affinity for FcγRI and for the antigen.

45. **(New)** The method of claim 41, wherein the antigen is selected from the group consisting of a viral, a bacterial, a parasitic, an allergen, a venom, and a tumor-associated antigen.

46. **(New)** The method of claim 45, wherein the antigen is an envelope glycoprotein of the human immunodeficiency virus (HIV).

47. **(New)** The method of claim 41, wherein the antigen-presenting cell is a macrophage, a monocyte or a dendritic cell.

48. **(New)** The method of claim 41, wherein the complex comprises:

(i) a first antibody, or fragment thereof which specifically binds to FcγRI without prevention by IgG; and

(ii) a second antibody, or fragment thereof, which specifically binds the antigen.

49. **(New)** The method of claim 48, wherein the complex comprises an Fab-Fab conjugate.

50. **(New)** The method of claim 41, wherein the complex comprises a fusion protein comprising an antibody or fragment thereof and the antigen.

51. **(New)** The method of claim 50, wherein the complex is produced recombinantly.

52. **(New)** A method for targeting an antigen to an antigen-presenting cell (APC), comprising contacting the APC with a preformed complex comprising:

a binding agent which binds to FcγRI on an antigen-presenting cell without being blocked by the natural ligand for the receptor, and

an antigen,

such that the antigen is targeted to the FcγRI receptor on the APC.

53. **(New)** The method of claim 52, wherein the binding agent comprises an antibody, or an antigen binding fragment thereof.

54. **(New)** The method of claim 52, wherein the antigen-presenting cell is a macrophage, a monocyte or a dendritic cell.

55. **(New)** The method of claim 52, wherein the binding agent comprises a bispecific antibody or a heteroantibody.

56. **(New)** The method of claim 52, wherein the antigen is covalently crosslinked to the binding agent.

57. **(New)** The method of claim 52, wherein the complex comprises a fusion protein comprising the antibody or fragment thereof and the antigen.

58. **(New)** The method of claim 57, wherein the complex is produced recombinantly.

59. **(New)** The method of claim 52, wherein the antigen is selected from the group consisting of a viral, a bacterial, a parasitic, an allergen, a venom, and a tumor-associated antigen.